SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Acetyl-CoA carboxylase 1 (ACC1) Carbamoyl phosphate synthetase 1 (CPS1) Carnitine palmitoyltransferase 1 (CPT1) Enolase 1 (ENO1) Formyltetrahydrofolate dehydrogenase, 10- (ALDH1L1) Fructose bisphosphate aldolase B (ALDOB) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Histone H2B Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) Very long-chain acyl-CoA dehydrogenase (VLCAD)
=== Preclinical === 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions ART-2612 (ART2612) – FABP5 inhibitor [25] BMB-202 – serotonin 5-HT2A receptor agonist [26] Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator) [27] Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H1 receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α1-adrenergic receptor antagonist) [28] GM-3009 (ibogaine analogue(s); GMX-3009) – various actions Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist [29] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABAA receptor positive allosteric modulator, benzodiazepine) Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen NB-127 – undefined mechanism of action [30] NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant [31] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent [32] Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors [33] TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen
==== Mycosporine-like amino acids ==== Mycosporine-like amino acids are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments.
== Conservation == Isinglass is also used as an adhesive to repair parchment, stucco, and damage to paintings on canvas. Pieces of the best Russian isinglass are soaked overnight to soften and swell the dried material. Next, it is cooked slowly in a double boiler at 45 °C (113F) while being stirred. A small amount of gum tragacanth dissolved in water is added to the strained isinglass solution to act as an emulsifier. When repairing paint that is flaking from parchment, isinglass can be applied directly to an area which has been soaked with a small amount of ethanol. It is typically applied as a very tiny drop that is then guided, with the help of a binocular microscope, under the edges of flaking paint. It can also be used to coat tissue or goldbeater's skin. On paintings, this can be used as a temporary backing to either canvas patches or filler until dried. Here, isinglass is similar to parchment size and other forms of gelatin, but it is unique in that as a dried film the adhesive can be reactivated with moisture. For this use, the isinglass is cooked with a few drops of glycerin or honey. This adhesive is advantageous in situations where minimal use of water is desired for the parchment as the isinglass can be reactivated with an ethanol-water mixture. It also has a greater adhesive strength than many other adhesives used for parchment repair.
Sources: en.wikipedia.org
The black mamba (Dendroaspis polylepis) is a large and highly venomous snake species native to much of Sub-Saharan Africa. It is the second-longest venomous snake species in the world and is the fastest-moving land snake, capable of moving at 4.3 to 5.4 metres per second (16–20 km/h, 10–12 mph). The black mamba is the most feared snake in Africa because of its size, aggression, venom toxicity and speed of onset of symptoms following envenomation, and is classified as a snake of medical importance by the World Health Organization. This species of snake shows tenacity, fearlessness, and aggression when cornered or threatened, during breeding season, or when defending its territory. They are also known to have up to a 100% rate of envenomation; the probability of dry bites (no venom injected) in black mamba strikes is almost non-existent. The venom of the black mamba is a protein of low molecular weight and as a result is able to spread rapidly within the bitten tissue. The venom is the most rapid-acting venom of any snake species and consists mainly of highly potent neurotoxins; it also contains cardiotoxins, fasciculins, and calciseptine. Based on the median lethal dose (LD50) values in mice, the black mamba LD50 from all published sources is as follows:
Resurgence of train ridership in the 21st century pushed the current Pennsylvania Station under Madison Square Garden to capacity, leading to several proposals to renovate or rebuild the station, often characterized as correcting for the 1960s demolition of the original facility. The Times noted in 2025 that a succession of elected officials over several decades—including Governors Pataki, Spitzer, Cuomo, and Hochul—had made gestures at reconstructing the station, though no such reconstruction ultimately materialized. Among the reasons, the Times cited the controlling interests of multiple transit companies—Amtrak, which owns the station, along with NJ Transit and the MTA, which operate within it—and the influence of James Dolan, whose company owns Madison Square Garden and the air rights above the station. Several of the failed plans were entangled with questions of if and how to move the Garden; in 2008, Eliot Spitzer induced the Garden to sign a memorandum of understanding to move one block west as part of a planned station reconstruction, although his plan fizzled after he was felled by a prostitution scandal only a week later. In 2013, the Regional Plan Association and Municipal Art Society formed the Alliance for a New Penn Station, advocating for limiting the extension of Madison Square Garden's operating permit to ten years and soliciting designs to move the arena.
In continuous-flow solution culture, the nutrient solution constantly flows past the roots. It is much easier to automate than the static solution culture because sampling and adjustments to the temperature, pH, and nutrient concentrations can be made in a large storage tank that has potential to serve thousands of plants. A popular variation is the nutrient film technique or NFT, whereby a very shallow stream of water containing all the dissolved nutrients required for plant growth is recirculated in a thin layer past a bare root mat of plants in a watertight channel, with an upper surface exposed to air. As a consequence, an abundant supply of oxygen is provided to the roots of the plants. A properly designed NFT system is based on using the right channel slope, the right flow rate, and the right channel length. The main advantage of the NFT system over other forms of hydroponics is that the plant roots are exposed to adequate supplies of water, oxygen, and nutrients. In all other forms of production, there is a conflict between the supply of these requirements, since excessive or deficient amounts of one results in an imbalance of one or both of the others. NFT, because of its design, provides a system where all three requirements for healthy plant growth can be met at the same time, provided that the simple concept of NFT is always remembered and practised. The result of these advantages is that higher yields of high-quality produce are obtained over an extended period of cropping.
On 4–11 February 1945 leaders from the United States, the United Kingdom, and the Soviet Union held the Yalta Conference where future arrangements regarding post-war Europe and Allied strategy against Japan in the Pacific were negotiated. They agreed that the boundaries of Germany as at 31 December 1937 would be chosen as demarcating German national territory from German-occupied territory; all German annexations after 1937 were automatically null. Subsequently, and into the 1970s, the West German state was to maintain that these 1937 boundaries continued to be 'valid in international law', although the Allies had already agreed amongst themselves that the territories east of the Oder–Neisse line must be transferred to Poland and the Soviet Union in any peace agreement. The conference agreed that post-war Germany, minus these transfers, would be divided into four occupation zones: a French Zone in the far west; a British Zone in the northwest; an American Zone in the south; and a Soviet Zone in the East. Berlin was separately divided into four zones. These divisions were not intended to dismember Germany, only to designate zones of administration.
==== MeSH D12.776.964.775.375 – gene products, pol (gene) ==== MeSH D12.776.964.775.375.325 – fusion proteins, gag-pol MeSH D12.776.964.775.375.335 – hiv integrase MeSH D12.776.964.775.375.340 – HIV protease MeSH D12.776.964.775.375.750 – RNA-directed DNA polymerase MeSH D12.776.964.775.375.750.375 – hiv-1 reverse transcriptase
Sources: en.wikipedia.org
The structures of opioids share many similarities. Whereas opioids like codeine, hydrocodone, oxycodone, and hydromorphone are synthesized by simple modifications of morphine, fentanyl and its relatives are synthesized by modifications of meperidine. Meperidine is a fully synthetic opioid, and other members of the phenylpiperidine family like alfentanil and sufentanil are complex versions of this structure. Fentanyl is a weak base that is highly lipid-soluble, protein-bound, and protonated at physiological pH. All of these factors allow it to rapidly cross cellular membranes, contributing to its quick effect in the body and the central nervous system.
==== Crosstalk ==== Many known phosphorylation sites and O-GlcNAcylation sites are nearby each other or overlapping. As protein O-GlcNAcylation and phosphorylation both occur on serine and threonine residues, these post-translational modifications can regulate each other. For example, in CKIIα, S347 O-GlcNAc has been shown to antagonize T344 phosphorylation. Reciprocal inhibition, i.e., phosphorylation inhibition of O-GlcNAcylation and O-GlcNAcylation of phosphorylation, has been observed on other proteins including murine estrogen receptor β, RNA Pol II, tau, p53, CaMKIV, p65, β-catenin, and α-synuclein. Positive cooperativity has also been observed between these two post-translational modifications, i.e., phosphorylation induces O-GlcNAcylation or O-GlcNAcylation induces phosphorylation. This has been demonstrated on MeCP2 and HDAC1. In other proteins, e.g., cofilin, phosphorylation and O-GlcNAcylation appear to occur independently of each other. In some cases, therapeutic strategies are under investigation to modulate O-GlcNAcylation to have a downstream effect on phosphorylation. For instance, elevating tau O-GlcNAcylation may offer therapeutic benefit by inhibiting pathological tau hyperphosphorylation. Besides phosphorylation, O-GlcNAc has been found to influence other post-translational modifications such as lysine acetylation and monoubiquitination.
==== Brands and forms ==== Oxymorphone was marketed by Endo Pharmaceuticals, under the brand name(s) Opana and Opana ER. Opana ER was withdrawn by the manufacturer in 2017 due to an FDA request, making it unavailable in the US. However, both IR (immediate release) and ER (extended release) formulations are still available under the generic names Oxymorphone and Oxymorphone ER and available from a multitude of manufacturers. Oxymorphone is also available as an injectable for inpatient use, available for IV (intravenous), IM (intramuscular), and SC (subcutaneous) injection. An extended release (ER) modified-release dosage form is commonly used, which modifies the pharmacokinetics of the drug.
Because of the practical and, in particular, the financial scale of the program needed, the NCI decided to seek association with a pharmaceutical company, and in August 1989, it published a Cooperative Research and Development Agreement (CRADA) offering its current stock and supply from current bark stocks, and proprietary access to the data so far collected, to a company willing to commit to providing the funds to collect further raw material, isolate taxol, and fund a large proportion of clinical trials. In the words of Goodman and Welsh, authors of a substantial scholarly book on taxol, "The NCI was thinking, not of collaboration, ... but of a hand-over of taxol (and its problems)". Although the offer was widely advertised, only four companies responded to the CRADA, including the American firm Bristol-Myers Squibb (BMS), which was selected as the partner in December 1989. The choice of BMS later became controversial and was the subject of Congressional hearings in 1991 and 1992. While it seems clear the NCI had little choice but to seek a commercial partner, there was also controversy about the terms of the deal, eventually leading to a report by the General Accounting Office in 2003, which concluded the NIH had failed to ensure value for money. In related CRADAs with the USDA and Department of the Interior, Bristol-Myers Squibb was given exclusive first refusal on all Federal supplies of Taxus brevifolia. This exclusive contract lead to some criticism for giving BMS a "cancer monopoly".
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.